Study finds chemotherapy antidote could improve recovery after chemotherapy-induced kidney toxicity

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data from 28 major U.S. cancer centers, the researchers examined the association between glucarpidase treatment -- which rapidly clears MTX from the blood -- and outcomes of patients with MTX-induced acute kidney injury (AKI). They found that patients who received glucarpidase had significantly higher chances of kidney recovery compared to those who did not get this treatment.

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data from 28 major U.S. cancer centers, the researchers examined the association between glucarpidase treatment -- which rapidly clears MTX from the blood -- and outcomes of patients with MTX-induced acute kidney injury (AKI). They found that patients who received glucarpidase had significantly higher chances of kidney recovery compared to those who did not get this treatment.

Read more https://www.sciencedaily.com/releases/2025/01/250106195925.htm